# US 2025/0152568 A1 · Methods of treating complex regional pain syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152568 A1
- Document ID: US20250152568A1
- Status: Published application
- Kind: A1
- Application number: 18/836,243
- Filed: 2023-02-06
- Published: 2025-05-15
- Earliest claimed: 2022-02-07
- Applicants: Aisa Pharma, Inc.
- Inventors: Andrew Sternlicht
- Web page: https://patentgrep.com/patent/US20250152568A1

## CPC

- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to methods of treating, e.g., complex regional pain syndrome (CRPS) using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).

## Claims

### Claim 1

A method of treating complex regional pain syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 2

A method of treating pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel; wherein the subject has complex regional pain syndrome.

### Claim 3 (depends on 1, 2)

The method of any one of claims 1-2, wherein the complex regional pain syndrome is identified or diagnosed in a leg of the subject.

### Claim 4 (depends on 1, 2)

The method of any one of claims 1-2, wherein the complex regional pain syndrome is identified or diagnosed in an arm of the subject.

### Claim 5 (depends on 1, 2)

The method of any one of claims 1-2, wherein the complex regional pain syndrome is associated with an injury in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the injury is a bone fracture or a crushing injury to a nerve.

### Claim 7 (depends on 1, 2)

The method of any one of claims 1-2, wherein the complex regional pain syndrome is associated with a stroke in the subject.

### Claim 8 (depends on 1, 2)

The method of any one of claims 1-2, wherein the complex regional pain syndrome is associated with a heart attack in the subject.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the complex regional pain syndrome is complex regional pain syndrome Type I.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the complex regional pain syndrome is complex regional pain syndrome Type II.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein after administration of the therapeutically effective amount of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel, the severity, frequency, and/or duration of burning or throbbing pain, sensitivity to touch or cold, swelling, increased or decreased perspiration, changes in skin temperature, changes in skin texture, changes in skin color, changes in growth rate of hair and/or nails, joint stiffness, muscle spasm, muscle weakness, muscle atrophy, excess bone growth, impaired movement, decreased range of motion of a joint, or any combination thereof are reduced in the subject.

### Claim 12 (depends on 2)

The method of claim 2, wherein the pain is neuropathic pain.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel exhibits at least a 50-fold selectivity for the N-type calcium channel over an L-type calcium channel.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel exhibits a 50-fold to 100-fold selectivity for the N-type calcium channel over an L-type calcium channel.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is selected from the group consisting of: cilnidipine, Z-160, CNV2197944, or pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is cilnidipine or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the dosage of the cilnidipine is from about 5 mg to about 25 mg.

### Claim 18 (depends on 16)

The method of claim 16, wherein the dosage of the cilnidipine is from about 9 mg to about 21 mg.

### Claim 19 (depends on 16)

The method of claim 16, wherein the dosage of the cilnidipine is about 10 mg.

### Claim 20 (depends on 16)

The method of claim 16, wherein the dosage of the cilnidipine is about 20 mg.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is administered orally.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein each administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is separated by at least about 8 hours.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein each administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is separated by at least about 24 hours.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein each administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is separated by at least about 48 hours.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein each administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is separated by at least about 1 week.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the period of administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is from about 1 day to about 1 month.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the period of administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is from about 1 day to about two weeks.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the period of administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is about two weeks.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the period of administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is about 12 days.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the period of administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel is about one week.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel further inhibits a Nav 1.7 sodium channel.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel further inhibits a TRPv-1 channel.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, further comprising determining that the subject has TRPv-1 overactivation.

### Claim 34 (depends on 33)

The method of claim 33, wherein determining that the subject has TRPv-1 overactivation comprises determining an abnormally high TRP-v1 current density in the subject.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the subject has a clinical record showing TRPv-1 overactivation in the subject.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, further comprising determining a decrease in TRPv-1 activation or upregulation in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, further comprising determining an abnormally high inflammation in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, further comprising determining a reduction in inflammation in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 39 (depends on 37, 38)

The method of any one of claims 37-38, wherein the inflammation is generalized, neurogenic, or both.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 1-39, further comprising determining that the subject has abnormally elevated concentrations of TNF-α, IL-1B. IL2, IL-6, ET-I, cGRP, bradykinin, substance P, MMP9, CXCL13, or any combination thereof before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 1-40, further comprising determining a lower concentration of TNF-α, IL-1B. IL2, IL-6, ET-I, cGRP, bradykinin, substance P, MMP9, CXCL13, or any combination thereof in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 42 (depends on 40, 41)

The method of any one of claims 40-41, wherein the abnormally elevated concentrations of TNF-α, IL-1B. IL2, IL-6, ET-I, cGRP, bradykinin, substance P, MMP9, CXCL13, or any combination thereof are measured in the cerebrospinal fluid or the plasma of the subject.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, further comprising determining that the subject has an abnormally high immunologic response, an abnormally high number or concentration of non-specific autoantibodies to sympathetic receptors, or both before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, further comprising determining a reduction in immunologic response, a reduction in number or concentration of non-specific autoantibodies to sympathetic receptors, or both after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, further comprising determining autonomic dysregulation; an abnormally high number of sympathetic receptors; an abnormally high concentration of circulating catecholamines; sympathetic hyperactivity; or any combination thereof in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 1-45, further comprising determining an improvement in autonomic functioning; a reduction in sympathetic receptors; a reduction in the concentration of circulating catecholamines; a reduction in sympathetic activity; or any combination thereof in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, further comprising determining an abnormally high central sensitization and neuroplasticity with increased substance P, bradykinin, and/or glutamate; an overexpression of spinal NMDA receptors; gabaminergic overactivity; or any combination thereof in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, further comprising determining a reduction in central sensitization and neuroplasticity with increased substance P, bradykinin, and/or glutamate; an overexpression of spinal NMDA receptors; gabaminergic overactivity; or any combination thereof in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 1-48, further comprising determining peripheral oversensitization; an abnormally high concentration of spinal N-methyl-D-aspartate; abnormally high concentration of spinal glutamate; upregulation in TNF-α and/or TRP-V1 activation; or any combination thereof in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 1-49, further comprising determining a reduction in peripheral sensitization; a reduction in spinal N-methyl-D-aspartate; a reduction in spinal glutamate; a reduction in upregulation of TNF-α and/or TRP-V1 activation; or any combination thereof in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 1-50, further comprising determining abnormally high oxidative stress, upregulation of superoxide dismutase, upregulation of one or more oxidative stress markers, an abnormally high concentration of reactive oxygen species, immune system overactivation, or any combination thereof in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, further comprising determining a reduction in oxidative stress, a reduction in upregulation of superoxide dismutase, a reduction in upregulation of one or more oxidative stress markers, a reduction in reactive oxygen species, a reduction in immune system activation, or any combination thereof in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1-52, wherein the one or more oxidative stress markers are selected from nitrotyrosine, isoprostane, malondialdehyde, myeloperoxidase, oxidized low density lipoproteins, and S-glutathionylation of haemoglobin.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1-53, further comprising determining that the subject has microvascular pathology and/or ischemia reperfusion injury before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, further comprising determining that the microvascular pathology and/or ischemia reperfusion injury in the subject is treated, improved, or ameliorated after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, further comprising determining endothelial dysfunction in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 1-56, wherein endothelial function in the subject is improved after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, further comprising determining an abnormally high stress response to cold sensitization and/or exposure in the subject before administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, further comprising determining a reduction in stress response to cold sensitization and/or exposure in the subject after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, further comprising administering an additional therapeutic agent to the subject.

### Claim 61 (depends on 60)

The method of claim 60, wherein the additional therapeutic agent is selected from the group consisting of: riociguat, amlodipine, pregabalin, gabapentin, nifedipine, nicardipine, conotoxins, cadmium, caroverine, levetiracetam, lamotrigine, NP078585, pregabalin, TROX-1, non-steroidal anti-inflammatory agents, valsartan, dimethylsulfoxide, N-acetylcysteine, N-acetyl cysteine, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, magnesium sulfate, ziconotide, analgesics, anesthetics, anticonvulsants, antidepressants, oral muscle relaxants, corticosteroids, calcitonin, bisphosphonates, cyclooxygenase (COX)-2 inhibitors, free-radical scavenger agents, prednisolone, prednisone, oral steroids, opioids, riociguat, amlodipine, pregabalin, alendronate, pamidronate, gabapentin, nifedipine, nicardipine, bupivacaine, epinephrine, caroverine, ascorbic acid, valsartan, dimethylsulfoxide, N-acetylcysteine, phenoxybenzamine.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1-61, wherein vasoconstriction in the subject is reduced after administering the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1-62, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, sympathetic tone diminution, direct smooth muscle relaxation, or both occur in the subject.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, burning pain, body temperature changes of the subject, thermal hyperesthesia, thermal hyperalgesia, changes in skin or tissue color, edema, changes in skin turgor, ruble, pallor, cyanosis, vasospasm, or a combination thereof are treated in the subject.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, nitric oxide is increased in the subject.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, oxidative stress in the subject is decreased.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 1-66, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, norepinephrine is reduced in the subject.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-67, wherein the subject is identified as normotensive; and wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, the heart rate and systolic blood pressure of the subject remains substantially the same.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-67, wherein the subject is also diagnosed with hypertension; and wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel to the subject, the systolic blood pressure of the subject is reduced.

### Claim 70 (depends on 69)

The method of claim 69, wherein the systolic blood pressure of the subject is reduced by greater than 1 mm Hg.

### Claim 71 (depends on 69)

The method of claim 69, wherein the systolic blood pressure of the subject is reduced by greater than 10 mm Hg.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 1-71, wherein after administration of the dual N-type and L-type calcium channel blocker selective for the N-type calcium channel, the bone density of the subject does not decrease.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 1-72, further comprising selecting a subject identified or diagnosed as having reduced bone density for the treatment.

### Claim 74 (depends on 73)

The method of claim 73, wherein the subject identified or diagnosed as having reduced bone density has osteoporosis.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 1-74, further comprising selecting a subject identified or diagnosed as having reduced renal function for the treatment.

### Claim 76 (depends on 75)

The method of claim 75, wherein the renal function of the subject is not reduced after treatment.

### Claim 77 (depends on 76)

The method of claim 76, wherein the renal function of the subject is improved after treatment.

### Claim 78 (depends on 77)

The method of claim 77, wherein improved renal function comprises a reduction in intrarenal arterial stiffness, improved blood flow to the kidneys, increased expression levels of podocyte proteins, or any combination thereof.
